VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LKFT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LKFTLakefront Biotherapeutics N.V.
$34.39$2.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLKFTRevenue History

LKFT logoLakefront Biotherapeutics N.V. (LKFT) Revenue History

Annual and quarterly revenue from 2004 to present

TTM Revenue$927.0M▼ $185.3M vs FY2025
YoY Growth-89.4%Declining
Q3 2026$7.5M-89.4% YoY · -37.8% QoQ
Revenue CAGR
3Y+66.4%
→
5Y+18.4%
→
10Y+39.6%
Growth accelerating ↑
Best Fiscal Year$1.11B (2025)
Best Quarter$900.8M (Q4 2025)
Revenue per Share$14.16

LKFT Revenue Over Time (2004–2025)

LKFT Revenue Growth History

14 of 21 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2004—
2005+44.5%
2006+212.7%
2007+87.6%
2008+16.7%
2009+20.9%
2010+31.5%
2011-21.7%
2012+42.1%
2013+1.1%
2014-49.6%
2015-43.0%
2016+227.4%
2017-1.9%
2018+127.3%
2019+189.1%
2020-42.7%
2021+1.4%
2022-50.2%
2023-0.6%
2024+15.0%
2025+303.5%
FY2004 revenue growth
N/A
FY2005 revenue growth
+44.5%
FY2006 revenue growth
+212.7%
FY2007 revenue growth
+87.6%
FY2008 revenue growth
+16.7%
FY2009 revenue growth
+20.9%
FY2010 revenue growth
+31.5%
FY2011 revenue growth
-21.7%
FY2012 revenue growth
+42.1%
FY2013 revenue growth
+1.1%
FY2014 revenue growth
-49.6%
FY2015 revenue growth
-43.0%
FY2016 revenue growth
+227.4%
FY2017 revenue growth
-1.9%
FY2018 revenue growth
+127.3%
FY2019 revenue growth
+189.1%
FY2020 revenue growth
-42.7%
FY2021 revenue growth
+1.4%
FY2022 revenue growth
-50.2%
FY2023 revenue growth
-0.6%
FY2024 revenue growth
+15.0%
FY2025 revenue growth
+303.5%
DeclineStrong growth
↑ 2-year growth streakBest: +303.5% (FY2025)Worst: -50.2% (FY2022)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q3 2026$7.5M-89.4%
Q2 2026$12.1M-81.4%
Q1 2026$6.5M-91.4%
Q4 2025$900.8M+1093.2%
Q3 2025$71.2M+18.9%
Q2 2025$65.3M-16.2%
Q1 2025$75.0M+20.1%
Q4 2024$75.5M—
Seasonal Revenue Pattern (fiscal quarters)
Q1
22%
Q2
30%
Q3
31%
Q4
17%

Multi-year avg. share of annual revenue by fiscal quarter

Revenue Breakdown (FY 2022)

LKFT's revenue distribution by segment and geography for fiscal year 2022

By Product/Segment

Upfront payments and milestone payments66.6%
Jyseleca33.4%

By Geography

United States97.2%
Europe2.8%

LKFT Revenue Analysis (2004–2025)

Current Revenue & Growth

As of November 18, 2026, Lakefront Biotherapeutics N.V. (LKFT) generated trailing twelve-month (TTM) revenue of $927.0 million, reflecting significant decline in growth of -89.4% year-over-year. The most recent quarter (Q3 2026) recorded $7.5 million in revenue, down 37.8% sequentially.

Historical Growth Trajectory

LKFT's 5-year compound annual growth rate (CAGR) stands at +18.4%, indicating consistent double-digit revenue growth. The 3-year CAGR of +66.4% exceeds the 5-year average, indicating an acceleration in the most recent period. Lakefront Biotherapeutics N.V.'s highest annual revenue of $1.11 billion was recorded in 2025, an all-time high.

Revenue by Segment

LKFT's revenue is primarily driven by Upfront payments and milestone payments (67%), and Jyseleca (33%). With over half of revenue concentrated in Upfront payments and milestone payments, the company has a focused business model while developing other growth vectors.

Peer Comparison

Compared to Healthcare sector peers — including ARCT (-72.9% YoY), ACAD (+14.8% YoY), and HALO (+45.0% YoY) — LKFT has underperformed the peer group in revenue growth. Compare LKFT vs ARCT →

LKFT Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
LKFT logoLKFTCurrent$927M-89.4%+18.4%45.1%
ARCT logoARCT$67M-72.9%+47.8%-111.5%
ACAD logoACAD$1.1B+14.8%+19.4%9.8%
HALO logoHALO$1.4B+45.0%+39.2%57.5%
EXEL logoEXEL$2.3B+9.1%+18.6%37.6%
IONS logoIONS$944M-0.7%+5.3%-40.5%
Best in groupLowest in group

LKFT Historical Revenue Data (2004–2025)

1–15 of 22 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$1.11B+303.5%$1.08B97.3%$501.4M45.1%
2024$275.6M+15.0%$240.8M87.4%$-188,338,000-68.3%
2023$239.7M-$239.7M100.0%$-88,263,000-36.8%
2022$241.2M-50.2%$241.2M100.0%$-131,056,000-54.3%
2021$484.8M+1.4%$483.2M99.7%$-165,597,000-34.2%
2020$478.1M-42.7%$-45,614,000-9.5%$-178,632,000-37.4%
2019$834.9M+189.1%$414.8M49.7%$368.7M44.2%
2018$288.8M+127.3%$-34,040,000-11.8%$-44,807,000-15.5%
2017$127.1M-1.9%$-91,415,000-71.9%$-89,802,000-70.7%
2016$129.5M+227.4%$-10,057,000-7.8%$-11,491,000-8.9%
2015$39.6M-43.0%$-90,151,000-227.9%$-89,444,000-226.1%
2014$69.4M-49.6%$-41,742,000-60.2%$-36,624,000-52.8%
2013$137.7M+1.1%$96.4M70.0%$-11,020,000-8.0%
2012$136.3M+42.1%$88.1M64.6%$-6,610,000-4.9%
2011$95.9M-21.7%$-29,099,000-30.3%$-32,935,000-34.3%
Consensus & Technical Research Suite
Open LKFT Terminal

LKFT Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

22+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LKFT — Frequently Asked Questions

Quick answers to the most common questions about buying LKFT stock.

Is LKFT's revenue growth accelerating or slowing?

LKFT revenue is declining -89.4% year-over-year. TTM revenue fell to $927M, contrasting with the 5-year CAGR of +18.4%. The reversal reflects either macro headwinds or company-specific challenges.

What is LKFT's revenue history from 2004 to 2026?

Lakefront Biotherapeutics N.V. (LKFT) revenue history spans 2004 to 2026. TTM revenue as of 2026 is $927M, growing at -89.4% YoY. The 5-year CAGR is +18.4%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is LKFT's long-term revenue growth rate (CAGR)?

Lakefront Biotherapeutics N.V.'s 5-year revenue CAGR of +18.4% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -89.4% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for LKFT.

Why does LKFT's quarterly revenue fluctuate?

LKFT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Lakefront Biotherapeutics N.V.'s revenue data from 2004 to 2026 shows full historical quarterly detail on this page.

How is LKFT's revenue distributed by segment?

LKFT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does LKFT's revenue compare to industry peers?

Lakefront Biotherapeutics N.V. (LKFT) with TTM revenue of $927M and -89.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.